In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunesis Pharmaceuticals Inc.

www.sunesis.com

Latest From Sunesis Pharmaceuticals Inc.

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Financing Business Strategies

Appointments: New Leadership At ABPI, CMOs Appointed At Acceleron and Biophytis

Pfizer's Erik Nordkamp has been named as the new president of the Association of the British Pharmaceutical Industry. Vant, Grail, Acceleron, Kite, Nimbus, Biophytis, Orchard Therapeutics, G1 Therapeutics, Almac Discovery, Athenex and Sunesis have also made key appointments.

Appointments BioPharmaceutical

Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m

Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.

Deals Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sunesis Pharmaceuticals Inc.
  • Senior Management
  • Dayton Misfeldt, Interim CEO
    William Quinn, SVP, Fin. & Corp. Dev. & CFO
    Judith A Fox, PhD, CSO
  • Contact Info
  • Sunesis Pharmaceuticals Inc.
    Phone: (650) 266-3500
    395 Oyster Pt. Blvd.
    Ste. 400
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register